Natrio Fluoridas (18f) Life Radiopharma (Sodium Fluoride (18f))

Natrio Fluoridas (18f) is used in the diagnostic imaging pathway for skeletal disease, providing high‑resolution PET images of bone turnover.

• Bone metastasis detection: enables sensitive PET imaging to locate metastatic bone disease.
• Skeletal imaging for cancer staging: assists clinicians in evaluating the extent of skeletal involvement.
• Evaluation of bone lesions: helps differentiate benign from malignant bone abnormalities.

• Sodium Fluoride (18F) dissociates to release fluoride ions that substitute for hydroxyl groups in hydroxyapatite, concentrating in areas of active bone remodeling. The fluorine‑18 isotope emits positrons, which are captured by PET scanners to generate detailed images of skeletal metabolism and pathology.

Adverse reactions may occur following intravenous administration of Natrio Fluoridas (18f).

Common Side Effects

• Injection site pain: mild discomfort at the site of administration.
• Nausea: transient feeling of queasiness.
• Flushing: brief warmth or redness of the skin.
• Headache: mild to moderate intensity.
• Dizziness: temporary light‑headedness.
• Metallic taste: brief sensation in the mouth.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Severe hypotension: marked drop in blood pressure.
• Radiation‑induced skin injury: localized erythema or ulceration.
• Organ toxicity: rare impairment of renal or hepatic function.
• Cardiac arrhythmia: abnormal heart rhythm in susceptible patients.

Prior to use, clinicians should consider several safety aspects.

• Pregnancy: unknown safety; avoid unless clearly needed.
• Breastfeeding: unknown safety; consider discontinuation.
• Renal impairment: assess kidney function before administration.
• Allergic history: evaluate for prior reactions to fluoride compounds.
• Radiation exposure: limit cumulative dose and follow local regulations.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before prescribing.

Major Interactions (Avoid)

• Calcium supplements: may reduce tracer uptake and affect image quality.
• Bisphosphonates: can alter bone turnover, leading to misleading results.
• Other radiopharmaceuticals: concurrent use may interfere with imaging interpretation.

Moderate Interactions (Monitor Closely)

• Vitamin D therapy: may influence fluoride incorporation into bone.
• Anticoagulants: increased risk of bleeding at injection site.
• Diuretics: potential alteration of renal clearance of fluoride.